HC-BP- Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products As a CDMO, Catalent notifies customers in accordance with the quality agreements it has in place with them and would inform the FDA and other applicable state and federal agencies, as required per policy and procedures, if there were ever an instance of counterfeiting that came to its attention.